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The discoveries of natural and the development of manufactured highly eﬃcient catalytic antibodies (abzymes) opens the door
to many practical applications. One of the most fascinating is the use of such antibodies in human therapy and prevention
(vaccination), of cancer, AIDS, autoimmune diseases. A special entity of naturally occurring DNA hydrolytic anti-DNA antibodies
is emerging within past decades linked to autoimmune and lymphoproliferative disorders, such as systemic lupus erythematosus
(SLE), multiple sclerosis (MS), Sjogren Syndrome (SS), B - Chronic lymphocytic leucosis (B-CLL), and Multiple Myeloma (MM).
The origin of the antibodies is unknown. The underlying mechanisms of these activities are suggested to be penetration into the
living cells and translocation in the nucleus, with recognition of the speciﬁc binding sites at particular (ss or ds) DNA. There are
controversies in the literature whether hydrolysis is a sequence-speciﬁc event. The interplay between anti-DNA antibodies and
DNA is not yet elucidated. This molecular “twist” also suggests that anti-DNA antibodies with DNA hydrolytic capacity could be
the organism’s immune response to a microbial attack, with microbial DNA, or speciﬁc genes within microbial DNA sequence, as
a target for neutralization. The catalytic antibody-based approach can become a key tool in selective chemotherapeutic strategies.
1.Introduction:HistoricalNotes
In 1957 [1], Ceppelini et al. reported that components
present in the sera from SLE patients were reactive with
DNA. These components were subsequently identiﬁed as
antibodies, and a broad spectrum of methods have been
developed in order to improve detection, characterization,
and quantiﬁcation of anti-DNA autoantibodies [2, 3]. These
methods were initially employed during investigations into
theroleoftheseantibodies inSLE,butlaterresearchrevealed
their occurrence in other autoimmune diseases. Yet, anti-
dsDNA autoantibodies are still considered by clinicians
the hallmark of lupus disease. Recently, an interest in
autoantibodies produced against ssDNA occurred in both
clinical[4–8]andexperimentalstudies[9–11].Keyquestions
regarding their presence and role in the development of SLE
and other autoimmune diseases remain. Recent studies on
the structure, function, and pathogenicity of both types of
autoantibodies revealed their dual function: hydrolysis of
DNA and cytotoxicity toward tumor cell lines [10, 12–14].
These functional features as both enzymes and cytotoxic
antibodies have recently been of keen interest in the clinical
arena [15, 16]. An understanding of the duality of these
uniqueantibodiesmayshedlightonthemechanismsoftheir
pathogenicity in SLE and other autoimmune diseases.
2. Anti-dsDNA Antibodiesversus
Anti-ssDNA Antibodies
2.1. Anti-DNA Antibodies and Their Correlation with SLE
Pathogenesis. Systemic lupus erythematosus (SLE) is a
chronic, potentially fatal autoimmune disease characterized
by exacerbations and remissions with various clinical man-
ifestations aﬀecting multiple organ systems, including the
skin, kidney, joints, cardiovascular, and nervous system. The2 Autoimmune Diseases
hallmark of systemic lupus erythematosus is the production
of an array of IgG and IgM autoantibodies directed against
oneormorenuclearcomponents,themostfrequentofwhich
are double stranded (ds) DNA and/or single stranded (ss)
DNA. Both anti-ssDNA and anti-dsDNA are involved in
disease development and have been eluted from the kidneys
of both experimental murine models and SLE patients [17].
Clinicians consider anti-dsDNA autoantibodies to be fairly
disease speciﬁc, while anti-ssDNA to be nonspeciﬁc. The
reasons for the diﬀerence in disease speciﬁcity are that there
is a test sensitivity of 60% for the anti-dsDNA antibodies
while the variability is 30%–70% for the latter [18]. The
level of anti-DNA antibodies varies in diﬀerent SLE patients’
plasma, with high levels of anti-ssDNA and/or anti-dsDNA
antibodiesbeingassociatedwiththeﬂareofsymptoms[4,5].
Consequently, the level of anti-DNA antibodies in patients’
sera is used to monitor disease activity and progression [4–
6].
The precise mechanisms leading to anti-DNA antibody
production remain unknown. The subsets of B-cell produc-
ersvaryaccordingtodiﬀerentauthors[19–21].Furthermore,
themechanismsofthepathogenicityofanti-DNAantibodies
and the immune complexes in SLE are disputed. Part of the
pathogenicity may be due to direct hydrolytic and cytotoxic
activityoftheanti-DNAantibodiesuponthecellsofdiﬀerent
tissues and organs that are aﬀected in the disease [18].
Pathogenic anti-DNA antibodies are able to interact at the
tissue level with alpha actinin in the glomeruli of kidney.
At the cellular level, the antibodies have been shown
to react with various cell surface proteins (e.g., myosin 1),
presumably allowing their penetration into the cell [22–25].
Upon entry into the cell, anti-DNA antibody is translocated
into the nucleus where it binds to DNA and consequently
hydrolyzes it. An alternative mechanism by which anti-DNA
antibody may lead to an autoimmune disease is through
its interaction with cell-death receptors, initiating a pro-
apoptotic signal that apparently leads to tumor cell death in
vitro and perhaps lupus B-cell death in vivo [12, 15, 26, 27].
Although the phenomenon is partially due to the activation
of caspase, the possible link between DNA hydrolysis and
programmed cell death, as well as underlying mechanisms
in SLE, are not clearly understood [12]. The diﬀerences
between natural and pathogenic anti-DNA autoantibodies
are summarized in Figure 1.
Beside their direct hydrolytic and cytotoxic eﬀects upon
the cells observed in vitro, the pathogenic mechanisms
involved in SLE include the induction of initial lesions via
deposition of circulating immune complexes (composed of
lupus DNA and antibodies bound to it) into the tissues of
various organs in vivo, thereby inducing an inﬂammatory
response leading to multiple organ/tissue damage in the
form of associating disorders such as systemic vasculitis,
glomerulonephritis, chorea, and others. The correlation of
these antibodies with SLE is undoubtedly established and
s u m m a r i z e di nF i g u r e2. The most important pathological
ﬁnding in nephritogenic lupus is the presence of immune
deposits beneath the glomerular endothelium in kidney
biopsies and virus-like particles in endothelial cells [28]. The
presence of virus-like particles in diﬀerent organs in patients
with lupus indicates that the anti-DNA antibodies could be
a part of the body’s viral or bacterial defense mechanism
involved in the removal of foreign DNA during the course
of the disease [29].
Anti-double-stranded DNA antibody is considered a
hallmarkoflupusdisease,foundinapproximately70%–90%
of patients with SLE (especially those with nephritis), and
measuring its levels in patient’s plasma is used to follow
the course of disease. However, since anti-single stranded
DNA antibody could be both hydrolytic and nephritogenic,
it may serve as a strong ﬂare predictor in the course of
the disease as well [4, 5]. The important role of anti-single
stranded DNA antibody is supported by ﬁndings in mouse
models of nephritogenic lupus in which only anti-ssDNA
antibodies were found [30]. Furthermore some anti-dsDNA
human antibodies are apparently not pathogenic l [7, 17].
Due to these controversies, a major goal in this ﬁeld of
research is to determine the optimal conditions for analysis
of the types and activity of highly puriﬁed human anti-
ssDNA (IgG and IgM) antibody, which could provide an
insight into their role in SLE pathogenesis. Achievement of
this goal could further develop means to produce highly
puriﬁed anti-DNA antibodies to be used in numerous
therapeutic studies. Highly puriﬁed antibodies may be useful
in constructing dendritic cell-based anti-idiotype vaccines
and idiotype peptides that may help regulate the disease
[31–38]. Some diﬀerences between anti-ds and anti-ss DNA
autoantibodies are shown in Table 1.
2.2. Isolation and Puriﬁcation of Anti-DNA Antibodies
2.2.1. Previous Attempts. Antibodies may play three impor-
tant roles in auto-immunne diseases: protective, predictive,
and pathogenic [40]. A major prerequisite for the study
of their roles in maintaining health or eliciting disease is
obtainingtheminhighpurity.Onefundamentalobjectionto
previous attempts at purifying anti-DNA antibodies directly
from human plasma by Kozyr [26] is that the process
yielded numerous bands on electrophoretic separation, and
some bands were inconsistent with the molecular weights
of IgGs. Furthermore, there was no attempt to separate
or to distinguish between the antibodies against ssDNA
and those against dsDNA, so the relative importance of
the pathogenic role the two types play in SLE or their
predictive role in the ﬂare could not be determined [4,
5]. Therefore, the development of a speciﬁc method for
isolation and puriﬁcation of each of the two categories
of anti-DNA antibodies with the highest level of purity
detected using a highly sensitive system, is highly desirable.
Such a method would allow parallel studies of the unique
functional activities of the two types of antibodies as well as
their speciﬁc role in the etiopathogenesis of SLE and other
autoimmune diseases. Since antibodies may form complexes
with other proteins, it is important to prove that the catalytic
activity ascribed to anti-DNA antibodies is not due to a
contamination with DNAse or some other hydrolytic protein
butdueto thefactthatit is an intrinsic, constitutive property
of the antibody alone.Autoimmune Diseases 3
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Natural anti-DNA antibody:
• In normal individuals
• IgG and IgM isotype with low aﬃnity
for ssDNA and dsDNA
• Not hydrolytic or cytotoxic
Pathogenic anti-DNA antibody:
• In SLE and B-CLL with autoimmune syndromes
• Hydrolytic and cytotoxic activity
• IgG( I gG1 and IgG3) and IgM isotypes with
higha ﬃnity for dsDNA and/or ssDNA Crystal X-ray structure of anti-ssDNA Fab regions
binding oligo-(dT)5 [49]
Figure 1: Diﬀerences between natural and pathogenic anti-DNA autoantibodies.
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• Hydrolysis of DNA after
translocation into the nucleus
• Cytotoxic eﬀect on the cells through
interaction with the death receptors
• Maintenance and perpetuation of
“vicious cycle”
• Formation of complexes with DNA and its
precipitation beneath endothelium of small
blood vessels (generalized vasculitis)
Figure 2: Lupus anti-DNA antibodies and their importance in SLE pathogenesis.
The methods created and applied in the past were mainly
done to detect the anti-DNA structural and functional char-
acteristics (e.g., substrate binding, hydrolytic, and cytotoxic
activity). A very reliable but laborious method was created
by Puccetti et al. [41] In this attempt, the IgG fraction was
boundtoproteinASepharose,eluted,andfollowedbynative
dsDNA cellulose in order to selectively capture anti-dsDNA
antibodies. The bound fraction was thereafter eluted from
dsDNA cellulose and dialyzed. The eﬄuent was absorbed
with poly-(dT) cellulose to bind anti-ssDNA antibodies and
the ﬁnal fraction was eluted with citrate buﬀer at a low
pH. Thus, both anti-dsDNA and anti-ssDNA fractions were
obtained and analyzed for their hydrolytic activity, either
separately or together. A major disadvantage of this method
is the loss of any IgG3 subclass antibodies since these do
not bind to protein A. The hydrolytic anti-DNA antibodies
were reported to be IgG1 and IgG3 classes. However, at the
time of the study, this was the only method available to
separate anti-ssDNA from anti-dsDNA after many laborious
steps using relatively speciﬁc substrates. Most of the authors
used DNA-cellulose puriﬁcation based upon the technique
pioneered by Moss et al. [3] wherein the DNA bound either
anti-ssDNA or anti-dsDNA or both directly from sera. This
methodisrelativelysimpleandgivesagoodyield(about70%
of anti-DNA antibody which maintains 100% binding and
hydrolytic activity). Gololobov et al. [42, 43] and Rodkey
et al. [30] used a modiﬁcation of this approach to purify
the mouse monoclonal anti-ssDNA antibody and its Fab
fragment (obtained by papain hydrolysis) with excellent
results with respect to their activity.
In [42] Gololobov et al.published amethod consisting of
two aﬃnity chromatography steps followed by ion exchange
and gel ﬁltration chromatography for the puriﬁcation of
antibodies from human serum that maintained DNA-
hydrolyzing activity. Antibody Fab fragments, obtained by
papain hydrolysis of antibody puriﬁed 130-fold, were shown
to catalyze plasmid DNA cleavage as determined by agarose-
gel electrophoresis and Linear Dichroism techniques. The
Fab fragment was shown to hydrolyze double stranded
supercoiled plasmid DNA by Mg2+ -dependent single strand
multiple nicking of the substrate. Such antibodies have
also shown ability to bind, but not necessarily hydrolyze,
single stranded regions which are undoubtedly present in
stretched double stranded DNA [44]. This type of hydrolysis
mechanism suggests that the Fab fragment could belong to
anti-ssDNA antibody and could be used as a criterion for
separating anti-DNA antibodies speciﬁc for ss- or dsDNA.
Characterization of antibodies that react with both ss- and
dsDNA will require further molecular analysis of their
structural, binding, and hydrolytic properties. To purify4 Autoimmune Diseases
Table 1: Anti-DNA autoantibodies in SLE both belong to category of ANA 95%–98% Titer: 1:80 or lower is considered negative.
dsDNA ssDNA
SPECIFICITY SPECIFICITY
(i) Highly speciﬁc for SLE [18] (i) NonSpeciﬁc [18]
(ii) Considered traditional markers of SLE (ii) Rarely indicated
TEST SENSITIVITY TEST-SENSITIVITY
(i) 60% (i) 30%–70%
PRODUCERS (?) PRODUCERS (?)
(i) 55%–75% of premature B-cells are prone to autoreactivity [18]( i ) C D 5 + / C D 5 - [39]
(ii) CD5+/CD5-[39] (ii) RP105- [19]
(iii) RP105-[19] (iii) RP105+ [19]
(iv) X = 19.5%
(v) (Range: 8.8%–31%)
DNA-hydrolyzing antibodies, the authors used protein A
after a 50% saturated ammonium sulfate precipitation and
dialysis of the isolated samples twice for 4 hours against
500 volume of Tris buﬀer, followed by MonoQ FPLC NaCl
gradient, subsequent glutaraldehyde-modiﬁed DNA cellu-
lose chromatography and Superose 12 gel ﬁltration FPLC.
Hence, the total IgG fraction with DNA-hydrolyzing activity
wasisolated;themethod,however,failedtoseparateds-from
ss-DNA antibodies. So, this extremely laborious technique,
lasting several days, was not highly selective with respect to
the substrate binding and speciﬁcity. Furthermore, protein A
does not bind IgG3, the subclass which is considered to be
highly hydrolytic.
In 1996, Kozyr modiﬁed the previous procedure by using
saturated ammonium sulfate for total IgG precipitation and
CibraconBlue3GAforfastalbuminremoval,followedbyion
exchange chromatography on DEAE-Sepharose FF, protein
G-aﬃnity chromatography for speciﬁc binding of the total
IgG fraction, and selection of DNA–binding fraction on
Sephacryl. After repeated dialysis, washing, and elution steps
a total anti-DNA hydrolyzing fraction was eluted in citrate
buﬀer, pH 2.6, and stored in PBS with 50% glycerol. This
was a very time-consuming procedure resulting in many
bands on electrophoresis other than anti-DNA antibodies
(IgGs). The author suggested that multiple bands resulted
from incomplete cleavage of S-S bonds by reducing agent.
Separation of the antibody subunits during puriﬁcation
procedure can generate such electrophoretic patterns. In
addition, enzymatic contamination of the puriﬁed antibody
still remained a strong possibility, since anti-DNA antibodies
are known to react with other proteins (laminin, ﬁbronectin,
alfa-actinin), phospholipids, and heparin sulfate.
Swanson et al. [17] reported the use of a protein-agarose
matrixcoveredwithssDNAinordertoisolateananti-ssDNA
antibody fraction of anti-DNA autoantibodies and checked
the binding activity of the fraction through poly-(dT) coated
ELISAplates(consideringthatpoly-(dT)isanimmunodom-
inant epitope). All of the monoclonal antibodies identiﬁed
in the ELISA screen recognized ssDNA, and several of them
cross-reacted with dsDNA (although with variable aﬃnity),
conﬁrmingthatanti-ssDNAantibodiesdocomprisethebulk
of lupus anti-DNA antibodies, and can react with both
ss- and dsDNA. The quality of this method however, is
not conclusive, since no analytical data was shown. To our
knowledge, it has not been utilized by other workers and
therefore, the advantages or disadvantages of the method
could not be evaluated.
In 1998, Kozyr et al. developed the ﬁrst aﬃnity-capture
assay (new in that they used paramagnetic Dynabeads to
purify anti-DNA antibodies) in order to prove the associa-
tion of DNA-hydrolyzing activity with the antibody fraction.
TheyincubatedbiotinylatedmouseantihumanIgG,withSA-
(Streptavidin-) coated paramagnetic beads, for 5 hours at
4◦C degrees. The anti-DNA puriﬁcation was performed on
a Sepharose column, followed by addition of the mixture of
antibodies to the beads in the ratio 2:1, and incubation for
1 hour. The SA coated beads which have bound biotinylated
mouse antihuman IgG complexes on their surfaces will have
human anti-DNA bound on the opposite end of the biotin
chain. After washing the antibody mouse-human complex in
the binding buﬀer and disrupting it with glycine-HCl (pH =
2.6), DNA abzymes were detached and free in the solution.
The beads were removed by the magnetic separation device,
the pH of the solution containing detached beads brought to
pH 7.5 with 1M Tris base and the ﬁnal preparation checked
forDNAhydrolyzingactivity.Thismethodisquitelaborious,
time-consuming, and utilizes harsh conditions to disrupt
antibody complexes followed by long overnight dialysis
treatments. The disruption event can adversely aﬀect the
binding and functional capacity of the antibody preparation.
In order to preserve the binding and functional properties
of antibody, gentler, faster means for puriﬁcation have been
sought.
2.3. A Novel Approach for Isolation and Puriﬁcation of ssDNA
Binding Anti-DNA Autoantibody. We have thus designed
a novel two-step, eﬃcient, fast, simple, and relatively
inexpensive method for isolation and puriﬁcation of anti-
ssDNA antibody that yields a high level of purity [9, 10].
Our methodology for puriﬁcation of anti-DNA antibody
is based on the ﬁnding that anti-ssDNA antibody has a
strong binding preference to thymine bases, conﬁrmed by
analysis of the crystal structure of a complex of oligo-
(dT) and mouse monoclonal anti-ssDNA antibody [42, 45].Autoimmune Diseases 5
Tanner et al. in 2001 illustrated the speciﬁc binding of anti-
DNA antibodies to thymidine polymers via arginine groups
using X-ray analysis. The arginine groups are responsible
for sequence recognition so that the antibodies bind the
DNA at the thymidine repetitive sequences (5mer) via
tyrosine side chains within a hydrophobic pocket created by
tyrosine and tryptophan from the antibody binding site. By
using biotinylated oligo-(dT) 20mer bound to streptavidin
coated magnetic Dynabeads, it was possible to isolate anti-
ssDNA antibodies speciﬁc for this single strand of thymine
nucleotides [10]. Dynabeads M-280 Streptavidin coupled
with Biotinylated oligo-(d) thymidine (20mer) were used to
isolate anti-DNA antibody directly from the patient’s serum
as the ﬁrst step, followed by further puriﬁcation of anti-DNA
antibody using protein G Dynabeads (known to bind total
IgG fraction) as a second step [9, 10]. The preparation of
oligo-dT beads is schematically presented in Figure 3.
Due to methods of puriﬁcation that in the past did not
clearly distinguish anti-ssDNA from anti-dsDNA autoanti-
bodies, it was unknown if the ELISA reaction is with the
DNA in double stranded or single stranded conﬁguration of
the loops which usually exist within stretched dsDNA, as it
was conﬁrmed by the work of Mostoslavsky et al. [46]. We
do know that the substrate for our anti-DNA antibody in
our ELISA plates was single-stranded DNA speciﬁc (oligo-
(dT)), and that it reacted exclusively with ssDNA-coated
ELISA plates. Obviously dsDNA may contain sequences of
repeated thymidine to which the apparently single strand-
speciﬁc antibody could bind.
However, Oligo-T-puriﬁed anti-ssDNA-IgG was of
extreme purity as evidenced by the appearance of a single
band following very sensitive silver-staining scale utilizing
the Pharmacia PhastGel electrophoretic staining method
(GE Healthcare, Piscataway, NJ; Owners Manual Separation
Technique File No.130), where there is between 0.3–0.5ng of
protein per band, and within the range of the sensitivity of
silver method applied, between 0.1–100ng of protein [46].
There may however be traces of other proteins or antibody
classes whose concentration falls below the level of detection
by silver staining.
The characteristics of Dynabeads make them suitable
for molecular puriﬁcation. Dynabeads M-280 Streptavidin
coupled with biotinylated oligo-(d) thymidine have an
excellent stability and a high lot-to-lot reproducibility due to
thelownonspeciﬁcbindingcharacteristicofstreptavidinand
high binding aﬃnity of the streptavidin/biotin interaction
(KD = 10–15) which allows for eﬃcient isolation of the
whole (intact) target molecules (no separation of subunits
in nonreducing conditions). The beads were blocked during
manufacturing procedure (personal report from the manu-
facturer) with 3% BSA to eliminate nonspeciﬁc binding for
SA and after that, kept in the storage buﬀer with 0.1% BSA.
It is known that some anti-DNA antibodies to Streptomyces
avidii (a rare cause of chronic respiratory infections in
humans) can bind to only SA-coated beads. Therefore, it
can be bound in the clefts between biotin molecules (since
1SA molecule binds a total of 4 biotin molecules on the
entire surface of 4SA subunits-one molecule of biotin per
one subunit of SA). Their interference in our system is
excluded due to the previous blockage of the beads which are
subsequently checked for the binding of puriﬁed antibody to
beads coated with SA alone. A dramatic drop was found in
the yield of anti-DNA antibody with recycled beads.
Protein G Dynabeads are designed for IgG isotype
puriﬁcation. Protein G has a strong binding aﬃnity to
four diﬀerent isotypes of IgG, and there is no leakage of
protein G from the bead surface beads during puriﬁcation.
Moreover, Dynabeads freely suspended in a solution can
be washed many times to eliminate nonspeciﬁc binding.
Another advantage of this method is that we can calculate
the optimal number of the beads required for the amount
of antibody determined by immunoassay. The oligo-(dT)
coupled to the SA Dynabeads is a 20-mer poly T which has
the feature of DNA, but is too short to bridge two antibody
molecules [17]. Because of the characteristic of oligo-(dT)
20mer, we are able to estimate the maximal amount of the
beads used to recover all anti-DNA antibodies from 1ml of
patient’s plasma. This makes the method very precise and
economical for application.
In summary, previously reported methods for anti-DNA
antibody isolation and puriﬁcation involved a combination
of biochemical and aﬃnity matrix steps, many of which
are nonspeciﬁc. Moreover, the abzyme (named according to
Linus Pauling, 1946) characteristic of anti-DNA antibody,
prone to denaturation under such harsh conditions, hinders
the routine use of these methods. Thus, nonspeciﬁc binding
and denaturation have been major issues regarding the
puriﬁcation of anti-DNA antibody. In order to explore the
structure, function and properties of anti-DNA antibodies,
many scientists shifted their attention to monoclonal anti-
DNA antibody generation. Mouse monoclonal antiss-DNA
antibody of the IgG isotype (IgG1and IgG3speciﬁcally) has
ah i g ha ﬃnity to antigen and has been shown to be
hydrolytic [30]. Although hybridoma technology is easily
applied for studies of autoantibody in mice, it is limited
for human autoantibody generation. The major problems
include immunization, the source of immune lymphocyte,
the limitation of the immortal fusion partner, and the unsta-
bility of the hybridomas. More importantly, the monoclonal
antibody does not represent the spectrum of anti-DNA
antibody subclasses present in a patient’s serum. To date no
information is present regarding the subclasses exhibited in
diseased versus normal human individuals. For that reason,
the development of a simple, speciﬁc and moderate method
of purifying anti-DNA antibodies from patient’s serum or
plasma, such as the 6-hr procedure with magnetic beads, is
important for the study of autoimmune disease.
To our knowledge, our lab was the ﬁrst to develop
a speciﬁc and simple method for isolating and purifying
human anti-DNA (IgG) antibodies from the SLE patients’
serum, based on the speciﬁc binding of anti-DNA antibodies
to thymine polymers (anti-DNA antibody base speciﬁcity is
dT   dG   dC ≥ dA) via arginine groups within the
antibody [3, 17, 45]. Based upon this ﬁnding, it was possible
toisolateanti-ssDNAantibodiesspeciﬁcforasinglestrandof
thymine nucleotides by using biotinylated oligo-(dT) 20mer
bound to streptavidin (SA)-coated magnetic Dynabeads
from Invitrogen (Carlsbad, CA) [10] .O u ra t t e m p t st op u r i f y6 Autoimmune Diseases
• T h eb e a dt oo l i go-(dT) ratio
is 1mgp er 1000pmol
• One oligo per one antibody
• Biotinylated oligo-(dT) 20mers
will be coupled to M-280
SA-coated magnetic dynabeads
Figure 3: Oligo-dT beads preparation.
anti-ssDNA antibodies using other oligomers (dC, dG, and
dA) bound to streptavidin-(SA-) coated Dynabeads were
unsuccessful.
The principle of two-step magnetic bead method for
puriﬁcation of anti-ssDNA is presented in Figure 4 and the
results of purity on SDS-PAGE in Figure 5.
3. Idiotypesandthe Role of IdiotypicNetwork
Idiotypes are the antigenic determinants of immunoglobulin
molecules that are located in the variable region of the
antibodies. Idiotypes are subdivided into those that reside
at the antigen-binding site, the paratope of the antibody
molecule, and those on the areas adjacent to this site, the
frameworkdeterminants.Thepotentialroleofidiotype-anti-
idiotype interreactions in the immune system stimulated
Jerne to postulate the presence of an “idiotypic network”
through which immunoglobulin expression might be con-
trolled[31].Idiotypicdysregulationisnowconsideredoneof
the major mechanisms that may underlie antibody-mediated
autoimmune disease.
According to Shoenfeld and Mozes, experimental SLE
could be induced in mice by anti-DNA idiotype immuniza-
tion and could be abrogated by anti-idiotypic and intra-
venous immunoglobulin treatment [47]. However, there are
also reports that idiotypic network can be used for the
production of catalytic autoantibodies [33].
4.DetectionMethods
As already mentioned, the presence of antibodies against
double-stranded DNA (dsDNA) is considered to be a
hallmark of Systemic Lupus Erythematosus (SLE) and thus
is used as one of the diagnostic criteria for the disease.
Recent research has shown that antibodies against single-
stranded DNA (ssDNA) may also play a critical role in the
course of the disease and in disease pathogenesis. However,
currently, physicians continue to focus only on monitoring
levels of anti-double stranded DNA antibodies in the blood
of patients diagnosed with lupus.
There are essentially three techniques used to measure
levels of anti-DNA antibodies in the blood:
(i) Crithidia lucilliae immunoﬂuorescence assay,
(ii) ELISA techniques,
(iii) Farr assay (radioactive).
The quantitative determination of anti-DNA autoantibodies
(particularly dsDNA) is useful for monitoring patients, par-
ticularly those with symptoms of nephritis. For monitoring
in these clinical cases, a quantitative assay is recommended
(Farr or ELISA-[48]).
4.1. Crithidium lucillae Immunoﬂuorescence Assay. Anti-
dsDNA autoantibodies are highly speciﬁc for SLE and are
present in a high proportion of SLE patients 40%–80%
[48]. Another method employs the microorganism Crithidia
lucillaefordiagnosticpurposesbecauseofitshighspeciﬁcity.
Authors/Commercially Available Kits. Zuess Scientiﬁc
Inc, Rarian, NJ, USA Commercially Available Kit., 2002). As
an alternative, Crithidia lucillae can be used in diagnostic
purposes for its high speciﬁcity.
Principle. Indirect immunoﬂuorescence assay—dsDNA
from the microorganism Crithidia lucilliae is used as the
substrate for anti-DNA antibody binding, and patient sera
diluted 1:10 are added to each well. After incubation, the
reaction is washed 3 times, and antigen-antibody reaction is
determined by FITC-labeled antihuman immunoglobulin.
An epiﬂuorescence microscope from Zeiss-Axiophot is used
to read the slides. A positive test is considered at a titer of
1:10orabove.
Range of Sensitivity. Qualitative—low sensitivity.
Cost. Average is $8.
Advantages. Simple, inexpensive, reliable, and more exten-
sively in use by the majority of clinical laboratories. The
main advantage of the assay is the presence of a highly stable
dsDNA that is concentrated in the kinetoplast (structure
involved in movement of the organism), thus giving very
high speciﬁcity of anti-dsDNA detection. The speciﬁcity of
the reaction is high and there is no use of radioisotopes. An
additional advantage is that the test requires little technical
expertise.
Disadvantages. Subjective, semiquantitative, and relatively
low sensitivity. Also, false positives are found sometimes due
the presence of antihistone antibodies (histones are proteins
that bind DNA). There is kit-to-kit variability due to the
preparation of the Crithidia lucilliae substrate.Autoimmune Diseases 7
SDS-PAGE electrophoresis Western blot Protein assay
Anti-DNA antibody quantiﬁcation
Recovery rate
Fibrin removal
Anti-DNA antibody isolation
Contaminant removal
Anti-DNA Ab binding and elution
Buﬀer exchange
Contaminant removal
Anti-DNA antibody IgG isotypee l u t i o n
Buﬀer exchange
Antibody storage
First step
Anti-DNA Ab IgG isotype puriﬁcation-protein.G
Second step
Figure 4: Scheme of two step magnetic bead based puriﬁcation of IgG from serum of patients with SLE.
4.2. Commercial Kits Using Diﬀerent ds- and ss-DNA as a
Substrate (ELISA). It is not advisable to use ELISA for diag-
nostic purposes due to its low speciﬁcity. The aﬃnity-linked
oligonucleotide nuclease assay (ALONA) was introduced by
Mouratou et al. [49]. This test uses digoxigenin coupled to
the 5  e n do fa3  -biotinylated DNA strand. In order to detect
catalytic anti-DNA antibodies which release the digoxigenin
from the substrate. This test is considered to be somewhat
more speciﬁc than ELISA itself, but still not as speciﬁc as the
Farr’s assay. In determining the level of anti-ssDNA, most
of the authors agree that either bacteriophage or plasmid
DNAshouldbeusedasasubstrateratherthancalfthymusor
any mammalian DNA. This preference is mainly due to the
long and fragile nature of mammalian DNA which usually
unwinds partially and binds ss-DNA antibodies in the test
systemforanti-dsDNAdetermination,creatingfalsenegative
results [5, 44].
Authors/Commercially Available Kits. Kits from
Diamedix Corporation, Miami, FL, USA; SCIMEDX
Corporation (for ds and ss DNA); ANTI-ssDNA Test from
AtlasLink; Diagnostic Automation Inc.; MESCUP DNA-II
TEST “ss” (for ssDNA); Helix Diagnostics, (dsDNA)West
Sacramento, CA
Principle. ELISA test; 96-well Micotiter plates are coated
with highly puriﬁed calf thymus ds or ss DNA. In each
well usually 100 microliters of diluted patient sera is added;
after incubation, each plate is washed 3 times. In addition
100 microliters alkaline phosphatase conjugated anti-human
IgG is added. After incubation and washing, the substrate is
added and the color development is read at 405 nanometers.
The results are expressed in international units per mL by
using a single point calibrator provided in the kit. A negative
value was considered as less than 100 international units per
mL. A value of 1–300IU/mL is considered borderline, and
greater than 300 is considered positive.
Range of Sensitivity. >300IU/mL
Cost. $4.80, when done single and $9.00, when done in
duplicate
Advantages. Good screening test for SLE; Immunoglobulin
class-speciﬁc antibody detection; No problem of isotope
disposal(noradioactivity);technicallyeasiertoperformthan
Farr.
Disadvantages. One of the most important problems with
the ELISA assay is determining what cutoﬀ level should be
usedwheninterpretingtheresults.Asecondimportantpoint
is the measurement and clinical signiﬁcance of low avidity
and/or IgM anti-dsDNA antibody of ELISA assay. Due to
great variations between diﬀerent kits and between samples
of the same concentration within the same kit, it cannot be
consideredhighlyreliable.Itisadvisabletoconﬁrmtheresult
of the ELISA with a more reliable assay like the Farr Assay
(RIA→ radioimmunoassay). Takes 4–6 hours to perform.8 Autoimmune Diseases
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Figure 5: Electrophoretic analysis of the purity of anti-DNA
antibody puriﬁed via two-step aﬃnity method employing magnetic
beads.
4.3. Farr Assay-Radioactive. This is the deﬁning assay for
detecting high avidity anti-dsDNA. It is also the method of
choice for detection of antibody to native double-stranded
DNA but should not be used as a screening test to detect
SLE [48]). This test is usually performed on patients already
known to have SLE, but is also performed on patients
who are screened for ANA (antinuclear antibodies) and are
reactive(havethesymptomsoflupus).Thenecessityofusing
radioactive material decreases its applicability.
Authors/Commercially Available Kits. Diagnostic Prod-
ucts Corporation, Los Angeles, CA, USA
Principle. I-125 labeled recombinant DNA (very pure) is
incubated with 25 microliters of patient sera. After incuba-
tion, bound antibody is carefully separated from unbound
antibody using ammonium sulfate, and the bound fraction
is counted by a gamma counter. The anti-dsDNA antibody
level is determined by using a standard curve prepared from
thepreviouslycalibratedstandardcurvebasedonWHOFirst
International WO/80 standard, which is provided in the kit.
Range of Sensitivity. >4IU/mL
Cost. $5.60, when done singly and $10.00, when done in
duplicate
Advantages. High sensitivity due to radioactive (iodine)
labeling of the substrate (DNA) takes about 3 hours to
perform highly pure recombinant human DNA and highly
pure bound fraction (precipitated by ammonium sulfate).
Disadvantages. Use of radioactive materials which require
safe handling and disposal no diﬀerentiation of isotypes of
the dsDNA antibodies; the test does not detect antibodies of
low avidity and/or low aﬃnity anti-ds antibody. Relatively
high level of technical expertise is required to perform the
test. A dilution series of sera giving >50IU/mL for exact
quantitation is necessary. Shelf-life of the kit is only 6 weeks.
5. Recognition, Binding, and
FunctionalActivities
What is the exact role of DNA-reactive antibodies in
lupus patients? What part of the abzyme possesses catalytic
activity? Fab fragment? Or could a single heavy or light
chain possess this activity? What is the exact role of these
antibodies in lupus? What part of their molecule possesses
catalytic activity? Fab fragment? Or either heavy or light
chain? Does the Fc fragment inhibit or interfere with the
enzymatic activity of the molecule as proposed by others?
[30, 43]. The later observation is particularly noteworthy as
it may aﬀord a means to regulate the activity of these unique
abzymes. It is somewhat puzzling that healthy individuals
as well as SLE patients produce anti-DNA antibodies which
can be isolated from their seruam [9, 10, 15, 50]. However,
normal individuals do not appear to be adversely aﬀected
by their presence, and their anti-DNA antibodies are not
hydrolytically active. Hydrolytic activity has only been seen
in anti-DNA antibodies produced in the disease state [15,
50]. Why are they then present in normal or apparently
healthy individuals? Catalytically active antibodies are found
in the sera and milk of pregnant and lactating women and
are considered to provide a maternal strategy to protect
against microbial attack of the fetus and newborns [10, 50].
In addition to anti-DNA antibodies, anti-RNA, NMP, NDP,
and NTP as well as antibodies with proteolytic activity
have been found in human sera of healthy and diseased
people, suggesting that the human host is trying to ﬁght a
microbial agent. Microbial DNA (bacterial and viral) is a
known immunogen and some authors suggest that a high
frequency of unmethylated CpG motifs in microbial DNA
acts as a stimulator of anti-DNA antibody production and
the ﬂare of symptoms seen in lupus. The CpG motifs act
throughbindingtotoll-likereceptor9(TLR-9)onBcellsand
plasmacytoid dendritic cells [10, 51, 52].
Studies show that anti-DNA antibody binds to peptide-
mimicking antigens which were synthetically designed,
some of which mimic viral or bacterial proteins [53].
One of the candidates for the appearance of anti-ssDNA
antibody could be the only known human ssDNA virus,
parvovirus B19 which has all possible characteristics [54]
of a causative/triggering agent (in at least a small frac-
tion) of lupus patients. Parvovirus can be found in most
humans as it resides in the erythroid precursor in a latent
state; however, symptoms only appear in a few patients.
However, when symptoms are displayed, they closely mimic
lupus symptoms. The spectrum of lupus symptoms and
the heterogeneous nature of the disease suggest that it is
probably caused and triggered by multiple environmentalAutoimmune Diseases 9
factors (similar to cancer) and therefore, requires individual
diagnosis, therapy, and prevention [18, 53, 55–57]. Perhaps
prevention of a fraction of lupus patients whose disease
is caused by parvoviruses is possible by early childhood
vaccination against the virus [10].
6. Mechanisms of Action
6.1. Recognition and Binding. Antibodies to DNA serve as
models for the study of protein-DNA recognition. For these
studies, monoclonal antibodies produced from hybridomas
were used. In many cases it is not possible to produce
suﬃcient Ig, mostly for these studies. Human monoclonal
antibodies, especially of the IgG isotype, were particularly
diﬃcult to obtain until the method of repertoire cloning was
developed [58, 59]. This approach enables the generation
of monoclonal antibodies of deﬁned speciﬁcity through the
molecular cloning of expressed Ab heavy (H) and light (L)
chains genes that are isolated directly from lymphocytes.
The genes are selected, based on their binding speciﬁcity
after in vitro expression [59]. An alternative approach is to
use computer-modeling techniques to examine the antigen-
combining sites of anti-DNA antibodies [60]. It has been
shown that anti-dsDNA autoantbodies prefer phosphate
backbone for binding [61–64] while anti-ss-DNA prefer
oligo-dT [17, 45]. Anti dsDNA also react with planted
antigen [17] and bind to cellular proteins [60, 65, 66]).
On the basis of experiments with monoclonal antibodies, it
was suggested that anti-dsDNA monoclonal autoantibodies
exhibited preference for DNA-binding motifs diﬀerent than
those of anti-ssDNA autoantibodies. Wang et al. [60]h a v e
shown that the fragments of ssDNA or dsDNA form bound
by the same stock of antibodies were diﬀerent in their
conserved sequences. Furthermore, ss-DNA fragments rec-
ognized by anti-DNA antibodies were rich in the following
nucleotide sequences:
-cacc
-caccg
-accc
-cccc blocks, while the same stocks of antibodies exhib-
ited signiﬁcant preference for −5  gcg 3 /3 cgc5  motifs
located in dsDNA [60]. According to Swanson’s binding
studies [17], both dsDNA and ss-DNA can deposit in patient
tissues and glomeruli via a process involving DNA binding.
Anti-ss-DNA Fab fragment denoted DNA-1 was isolated
from a combinatorial bacteriophage display library of IgG
fragments derived from the immunoglobulin repertoire of
an autoimmune SLE MRL/lpr mouse. This fragment binds
to oligo-(dT) 15 nucleotides or greater in length with a
Kd of 140nM. The Kd values for poly dG, dC, and dA
being of 1–10uM indicated its marked preference for oligo
(dT). Furthermore, Tanner et al. [45] revealed the crystal
structure of monoclonal mouse anti-ssDNA autoantibody,
for example, a crystal structure of recombinant Fab (DNA-
1) in complex with dT5 (Thymidine pentamer). The avail-
able crystal structures indicate that DNA binding causes
signiﬁcantconformationalchangesin the antibody, probably
leading to catalytic activity. It is widely believed that high
arginine content is a fundamental property of the hypervari-
able loops of both anti-dsDNA and anti-ss-DNA antibodies
from lupus prone mice and SLE patients. Indeed, the aﬃnity
of autoimmune antibodies for dsDNA can be increased by
introducing Arg into the H3 domain, while elimination of
Arginine has been shown to reduce the aﬃnity for dsDNA.
Likewise, Arg in H3 is thought to be critical for binding ss-
DNA. Crystal studies of Tanner et al. [45] suggests that in the
case of mouse monoclonal antibody BV-04 Arginine within
the antibody is responsible for recognition while Tyrosine is
needed for the binding to the sliding thymidine pentamer.
For some reason the pentamer is necessary to attract the
antibody but only T1, T3, and T4 are involved in binding
[45]. At present, no crystal structure of an anti-dsDNA
antibody that is complexed with its antigen is available.
Although diﬀerent mechanisms are used for binding ss and
ds ligands, the mode of DNA recognition appears to be
conserved within groups of antibodies [17]( T a b l e2).
The pathogenic anti-DNA antibodies might have dual
activity: hydrolysis and cytotoxicity, the latter at least
expressed toward certain tumor cell lines [13, 14].
6.2. Hydrolysis: Mechanism of Action. The prerequisite for
binding of anti-DNA antibodies is the recognition of either a
phosphosugar backbone of dsDNA (for anti dsDNA autoan-
tibodies) or a thymidine pentamer in ssDNA (for antiss-
DNA autoantibodies) while the prerequisite for hydrolysis is
binding itself. In der to hydrlolyze DNA, antibody must be
tightly bound to it. According to Kozyr [14], only a certain
subset of anti-DNA autoantibodies reveals the features of
DNA hydrolysis (70%) and tumor cell line cytotoxicity
(30%), thus outlining the presence of speciﬁc functionally
active structures. For at least one mouse monoclonal anti-ss-
DNA autoantibody (BV04-01), the active center is known to
be HisL27, which intercalates between the second and third
thymidine residues in ss-DNA. This anti-ssDNA autoanti-
body has been proven to have hydrolytic activity in the
presence of Mg2+ and Ca2+ with Mg2+ acting at the center
of the active site, while Ca2+ accelerates hydrolysis. Catalysis
was associated with Fab and single-chain antibody proteins
[30]. According to the same author, the percentage of DNA-
hydrolyzing antibodies in SLE patients was 42%, while in
B-cell tumors it was 52%. Very recently, the studies of
Parkhomenko et al. [67] have shown that hydrolytic activity
is localized in the light chains of the antibody molecule. The
other details of the process are unknown. Further research is
necessarytorevealthespeciﬁcityofantibodiesfornucleotide
sequences and kinetics of hydrolysis. The initial data, based
on the novel real-time ﬂuorescent assay [68] (Figure 6),
suggest that the reaction diﬀers fundamentally from isolated
DNAse I activity, indicating that it is an intrinsic property
of the antibody itself [69] (Figure 7). Are the cytotoxic and
hydrolytic active sites of the abzyme seen in lupus patients
located in the same or diﬀerent parts of the molecule?
6.3. Cytotoxicity: Mechanism of Action. Only 30% of anti-
DNA autoantibodies isolated from the patients with either
CLL or SLE revealed antibody cytotoxicity to tumor cell10 Autoimmune Diseases
Table 2: DNA recognition and binding by anti-DNA autoantibodies.
dsDNA ssDNA
DNA-Recognition Mechanisms DNA-Recognition Mechanisms
(i) Elusive (i) Arginine involved [45]
DNA BINDING DNA BINDING
(i) DNA phosphate backbone [61–63] (i) Oligo-dT [17, 45]
(ii) Planted antigens [17] (ii) Involvement of tryptophan and tyrosine in binding [17]
(iii) Cellular membrane proteins [65, 66] DNA-binding MOTIFS
DNA-binding MOTIFS (i) -cacc-caccc-accc-cccc blocks [60]
(i) 5  gcg 3 /3 cgc5 motifs located in dsDNA [60].
Donor
ﬂuorescence
J(λ)
Wavelength (λ)
Acceptor
absorption
I-I-I
I-I-I-I
I-I-I-I-I-I-I
Figure 6: Continuous ﬂuorescence-based hydrolysis assay.
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Figure 7: Kinetic parameters of DNAse 1 and lupus anti-ssDNA antibody.Autoimmune Diseases 11
lines [27]. In only one case of each disease did DNA speciﬁc
antibodies exert catalytic activity that did not accompany
cytotoxicity, suggesting diﬀerent active sites in these excep-
tions. It seems that there may be several mechanisms of cyto-
toxicity induced by these antibodies. Cytotoxicity is detected
at an antibody concentration of 10−8–10−10 M, which is
comparable to the cytotoxicity of TNF-α. Time-dependent
proﬁle of anti-DNA antibody cytotoxicity has revealed two
distinct peaks by 3 and 18–48 hours when L929 cells
were incubated with 10nmols of anti-DNA antibodies. [13]
Suchkov, et al., (2001) in trying to explain the underlying
mechanisms of cytotoxicity, suggested that several apoptotic
mechanisms could be involved considering initial activation
of caspase at the early stages of the anti-DNA antibody
action on the cells. Kozyr et al. [14] suggested that the
mechanism of interaction of the antibodies within the cells
might be cell cycle-dependent. These data may outline the
pathogenic role of DNA-hydrolyzing autoantibodies upon
entering the nucleus, thus contacting with chromatin (cross
reaction with nuclear matrix proteins) and causing DNA
cleavage through induction of apoptotic pathways, with
consecutive cell death. Anti-DNA antibody-mediated cell
death may be attributed to activation of signal transduction
pathways and apoptosis. Alternatively, anti-DNA antibodies
may enter the cell and either block protein synthesis or, in
case of DNA hydrolyzing antibodies, cleave DNA. Part of the
pathogenicity of anti-DNA autoantibodies might be due to
celldestruction,leadingtothereleaseofnuclearcontentsand
thus new antigens into the blood stream with perpetuation
and maintenance of the anti-DNA autoantibody production.
The functional properties of anti-dsDNA and anti ss-DNA
antibodies are summarized in Table 3.
7. Pathogenicity
There is no general consensus regarding the mechanism of
pathogenicity and possible diﬀerences in the pathogenicity
between anti-dsDNA and anti-ss-DNA autoantibodies in
SLE. Some authors consider anti-dsDNA to be pathogenic,
while anti-ss-DNA is nonpathogenic. Those who consider
anti-dsDNA autoantibody to be pathogenic describe it as
ah i g ha ﬃnity cationic IgG molecule (preferentially of
IgG3 isotype) that binds dsDNA and ﬁxes complement.
These complement activating immune complexes are thus
considered the cause of general vasculitis and especially,
glomerulonephritis [55]. The variable region of autoanti-
body exhibits somatic mutations and is enriched with acid
residues that are appropriate for DNA binding. The presence
of Arg on DC-R-H3 is particularly notable. However, Ehren-
stein et al. [70] suggested that anti-dsDNA is not pathogenic
at all. Swanson [17] has shown that some monoclonal anti-
dsDNA antibodies are pathogenic, while some of them are
benign. In the same experiment he showed that anti-ss-
DNA can be even more pathogenic than anti-dsDNA, as
judgedbythebindingactivity.Thelaterresultsaresupported
by the work of Sun et al. [71]. Aotsuka and Yokohori
[4] have found that anti-ssDNA antibodies of IgG class
showedasigniﬁcantlyhighervalueinseracomparedtoother
isotypes and correlated well with lupus urinary abnormality.
He also noticed that there were the patients with SLE in
an active disease who presented with increased levels of
anti-ss-DNA antibody (IgG class) just prior to the disease
period (reported in MESACUP DNA TEST “ss” medical
and Biological Laboratories, Inc). Teodorescu [5]p e r f o r m e d
a longitudinal clinical study in a group of lupus patients
and concluded that levels of anti-ss-DNA autoantibodies
are the best predictors of a forthcoming increase in dsDNA
levels and the SLE symptom ﬂare. Beckingham et al. [6]
considers anti-ss-DNA pathogenic because of its sequence
recognition of ssDNA and binding and pointed to the
strategies for disrupting DNA binding that could prove to
be therapeutically useful. Quite recently, Chen [9], Pavlovic
et al. [10, 72] used self-created magnetic oligo-dT beads
for the isolation of a highly pure human lupus anti-ss
DNA antibodies. The later have shown hydrolytic activity
upon a ssDNA probe in a sophisticated newly designed [68]
ﬂuorescent real-time assay system and related the enzyme
activitytothepathogenicroleoftheseantibodies.Whatisthe
physical basis for the diﬀerential pathogenicity? What makes
some anti dsDNA autoantibodies clearly more pathogenic
than others? Kalsi et al. [18] suggested that pathogenicity
might not be related to the charge and aﬃnity of anti-DNA
autoantibody, but to its ﬁne binding speciﬁcity. Perhaps B
cellsrespondingtotheﬂareinreplicationofasinglestranded
viral agent, like parvovirus, initially produces a wave of
anti-ssDNA antibodies. As the immune response continues
in an eﬀort to control the agent, aﬃnity maturation and
epitope spreading within the B cell’s progeny may lead to the
production of anti-dsDNA antibodies. If the single stranded
viral agent utilizes double stranded replicative intermediates,
the necessity of producing hydrolytic antibodies becomes
evident. Should the viral agent reside within the nucleus,
perhaps cytotoxic antibodies play a key role in host defense
against these agents. However, the role of anti-DNA anti-
bodies in humoral defense against viral agents has not been
investigated and remains an untapped ﬁeld of investigation.
8. Treatment
8.1. Plaquenil. These are antimalarial drugs, particularly
eﬀective for joint pain, rashes, and mouth ulcers (about
50% patient’s response). They are very safe, except for some
concerns regarding retinal toxicity. The drug is sometimes
recommended to pregnant women as there have been no
cases of defects in the newborn, and there is a risk of
a ﬂare in disease symptoms in the mother if the drug is
discontinued. The mechanism of action of these drugs is not
known. However, recently, it has been shown that palquenil
acts through TLR9 by decreasing the production of anti-
DNA autoantibodies in patients with rheumatoid arthritis
[51, 73]. This ﬁts into the “Theory of innate immunity“
recently applied to SLE (Figure 8)[ 51] and lends credence
to the role of microbial DNA in eliciting the disease.
8.2. B-Cell Depletion Therapy. Rituximab is a chimeric
(human/mouse) monoclonal antibody that is speciﬁc for12 Autoimmune Diseases
Table 3: Anti-DNA autoantibodies properties.
dsDNA antibodies ssDNA antibodies
Ig class: IgG and IgM Ig class: IgG and IgM
IgG subclass: IgG3 IgG subclass: IgG1 and IgG3
PATHOGENICITY: based upon binding criteria PATHOGENICITY: based upon binding criteria
(i) Some forms of lupus nephritis (i) Non-pathogenic?
(ii) CNS involvement (ii) Pathogenic and nephrogenic in human and murine models
(iii) Correlates with disease activity (iii) Predictors of lupus ﬂares and anti-dsDNA increase in humans
Abzymes and DNA-hydrolytic activity ABZYMES and DNA-HYDROLYTIC ACTIVITY
Human and mouse mono- and polyclonal Mouse monoclonal. Human?
CYTOTOXIC ACTIVITY CYTOTOXIC ACTIVITY
Human polyclonal Undetermined···for now
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Figure 8: The innate model of lupus pathogenesis.
the B-cell surface marker CD20 and aims towards B cell
depletion. It is currently used to treat leukemias and
lymphomas. Recent studies and clinical trials have shown
successful results in SLE treatment [74]. Initially, investiga-
tors theorized that by removing the anti-DNA producing B-
cells, they would be replaced by new nonself reactive B cells
that would produce protective antibodies. The clinical trials
involving patients with rheumatoid arthritis and lupus are
ongoing.IntheMedizinischeKlinik,Univeristatsklinikum in
Freiburg, Germany, treatment with Rituximab successfully
and dramatically improved a 59-year-old women’s life,
which was unresponsive to the typical SLE medications
such as methotrexate, corticosteroids, and azathioprin. This
patient went into complete remission 18 months after the
treatment was completed. The results from other studies
[75–77] indicate that while patients are under the treatment
the anti-DNA antibodies disappear leading to remission of
symptoms.Eventually,theﬂaremayreoccurinsomepatients
and therefore, this kind of therapy is not causal as it was
curative as expected. Deeper knowledge at the causative level
of SLE is necessary in order to eﬀectively cure the disease.
In terms of therapeutical approach, it is worth to mentionAutoimmune Diseases 13
the work of [35, 57, 78] on anti-DNA antibody. Idiotypic
vaccinesdevelopedanti-DNAantibodyvaccinesinmice.The
approach was to load dendritic cells with anti-DNA idiotype
in order to elicit cytotoxic T cells which would destroy the
lupus B cell. This approach is in developmental stage and
requires more basic knowledge of immunology.
9. Induction and Regulation of Anti-DNA
Antibody Responses by
EnvironmentalFactors
9.1. Phthalate, Pristane, and Vaccines. Environmental sub-
stances are considered important triggers of the disease state
in lupus patients. They entail infectious agents, chemicals,
drugsandevenvaccines.Littleisknownoftheroleofspeciﬁc
environmental factors in promoting autoimmune disorders
such as systemic lupus erythematosus (SLE). Lim and Ghosh
in 2005 conducted a study on how exposure to phthalates,
common environmental factors in foods, and biomedical
devices could aﬀect the immune functions of resistant and
autoimmune-prone mice. They have previously shown [79]
that immunization with orthophthalate evokes anti-DNA
antibody in BALB/c and NZB/W F1 mice, but only the latter
suﬀered from nephritis and high mortality. BALB/c mice,
in contrast, developed idiotype-speciﬁc CD8+ suppressor T
cells (Ts) that downregulated autoreactive B cells. In their
following study they reported that all phthalate isomers
(ortho-, meta- and para-) are capable of inducing anti-
DNA antibody responses and SLE-like syndromes. Kidney
pathology worsens in NZB/W F1 and to a degree, in
C57BL/6 mice after repeated exposure to phthalates [80].
Only BALB/c and DBA/2 overcome adverse autoreactivity
by induction of Ts cells, but in vivo depletion of these T
cells renders these strains susceptible to autoreactivity. Anti-
DNA antibodies in aﬀected NZB/W F1 are largely IgG2a-
type, while in BALB/c, DBA/2, and C57BL/6 mice IgG1-
type.This wasfurthercorroboratedbycytokine analysesthat
implycorrespondingTh1/Th2involvement.Insummary,the
commonly used phthalates appear harmful to susceptible
strains,whileBALB/candDBA/2aresparedduetoinduction
of Ts cells. Ts cells have a known eﬀect of suppressing
polyclonal B-cell expansion, the event which consecutively
leads to lower anti-DNA autoantibody secretion. It would
be revealing to determine if any human lupus patient has
antibodies reactive toward isomers of pthalates and if healthy
individuals possess T suppressor cells for this common
environmental contaminant. Other environmental factors
aﬀecting anti-DNA autoantibody production involve pris-
tane [81], vaccination with minigenes [82]o rp C o n s e n s u s
peptide [83]. These agents possess inducing mechanisms
similar to that of phthalates, with B-cell ablation by Ts cells
again seen in nonsusceptible strains of mice.
9.2. Drugs. We have already described the drugs which
are the most eﬀective for anti-DNA antibody decrease and
temporary disappearance. There is also a spectrum of drugs
which cause so-called “drug-induced lupus”, but interest-
ingly, these patients do not present with detectable anti-
DNA autoantibodies. Therefore, in drug-induced SLE there
is no nephritogenic syndrome and all signs and symptoms
usually subside when the critical medication is no longer
administered.
9.3. Infectious Agents and Production of
Anti-DNA Autoantibodies
9.3.1. State of the Art: Innate Immunity and Possible Condi-
tions for Production of Anti-DNA Antibodies in Autoimmune
Diseases. Recent studies have shown that infectious agents
such as viruses, bacteria, parasites, fungi, and other organ-
ismshavevariableeﬀectsonautoimmunedisease,caninduce
autoimmune disease, enhance autoimmune disease; or even
abrogate or oﬀer protection from autoimmune diseases [46,
55, 84–90]. Increasing evidence shows that our immune sys-
tem’s normal response to infection results in an amelioration
of autoimmune disease symptoms and protection against
autoimmune disease development. This evidence supports
the theory known as the hygiene hypothesis, which states
that increased use of antibiotics, antibacterial and antiseptic
cleaning agents, and vaccines leads to an enhanced incidence
of autoimmune disorders, asthma, and allergies [84].
9.3.2. Infection and Protection. Normally, infection of target
cells and organs causes the release of sequestered (normally
hidden from the blood circulation) autoantigens (self-
protein particles) [84, 85]. Antigen presentation to immune
system cells is thereby enhanced. Although these antigens
normally provoke a heightened inﬂammatory response,
some of them can activate regulatory T-lymphocyte cells,
which dampen rather than evoke aggressive immune
responses. Cytokines and chemokines released during the
immune system’s response to infection can direct aggressive
T lymphocytes to the site of infection, drawing them from
the autoimmune process. The autoimmune process that
orchestrates production of anti-DNA autoantibodies seems
to involve both innate and acquired immunity including
Toll-Like Receptors, Inﬂammasomes, DNA-sensing proteins
and transcription factors. The details of mechanism of
secretion are still not known, but within last few years the
emerging knowledge indicates that liaisons of the pathway(s)
are becoming clearer.
Toll-Like Receptors (TLRs). TLRs are arguably the most
studied of the pattern recognition receptors (PRRs) [89–
92]. They are transmembrane receptors that recognize
individual pathogen-associated molecular patterns (PAMPs)
on invading microbes. The intracellular tail contains a highly
conserved region, called the Toll-interleukin-1 receptor
(TIR) domain, which mediates interactions between TLRs
and downstream signaling molecules [91].
Recognition of PAMPs by the TLRs triggers a series
of events leading to the expression of many immune
and inﬂammatory genes. TLRs also induce dendritic cell
(DC) maturation, which is essential for the induction of14 Autoimmune Diseases
pathogen-speciﬁc adaptive immune responses. One of the
important lupus signature is the secretion of Interferon α by
plasmocytoid dendritic cells ( pDC)(92). To date, 10 TLRs
(TLR1-10) in human and 12 TLRs (TLR1-9 and TLR11-13)
in mice have been described [92].
TLRs are expressed on a range of immune cells, which
include macrophages, DC, B cells, and certain types of T cells
[90]. They are also expressed on certain nonimmune cells,
such as epithelial cells, which lie at potential sites of entry,
including the skin, respiratory, intestinal and genitourinary
tracts, endothelial cells, and smooth muscle cells. Their
pattern of expression is modulated by activation, maturation
or diﬀerentiation of the diﬀerent cell types. TLRs 3, 7, 8,
and 9 are expressed intracellularly, while TLRs 1, 2, 4, 5,
6, and 10 are expressed on the cell surface [89]. Brieﬂy,
TLR2, which works with TLR1 or TLR6, recognizes bacterial
components, such as lipopeptide and lipoprotein of gram-
positive bacteria; speciﬁcally, the heterodimer TLR1/2 which
can recognize triacyl lipopeptide, while TLR2/6 recognizes
diacyl lipopeptide.TLR7 is documented to recognize RNA,
while TLR9-DNA, both microbial and self [89, 90].
Inﬂammasomes. Inﬂammasome is a name given to a large,
signal-induced multiprotein complex that mediates the acti-
vation of proinﬂammatory caspases [93–95]. As a multipro-
tein complex it mediates the release of interleukin-1β from
cells in response to infection by various pathogens or other
danger signals. Interleukin-1β is a potent proinﬂammatory
cytokine released from cells upon infection which triggers as
well as directs the innate and adaptive immune response.
Quite recently, Muruve et al. [94] have reported that the
inﬂammasomerecognizespotentiallydangerouscytoplasmic
microbial or viral DNA and triggers an innate immune
response [94]. Endosomal Toll-like receptor 9 (TLR9) and
the cytoplasmic sensor DNA-dependent Activator of IFN-
regulatory factors (DAI, also known as ZBP1) have previ-
ously been identiﬁed as intracellular receptors for DNA that
trigger a type I interferon (IFN) response. Now, Muruve
et al. report that activation of the inﬂammasome is also
important for the generation of an eﬀective inﬂammatory
response to adenoviruses and other DNA viruses [94]. For
example, infection of the human monocyte cell line THP-
1 with adenovirus or herpesvirus led to pro-interleukin-
1β (IL-1β) maturation and caspase-1 activation, which are
both indicators of inﬂammasome activation. These eﬀects
were absent following treatment with empty viral capsids or
extracellular adenoviral DNA, indicating that neither virion
internalization alone nor extracellular DNA could trigger the
inﬂammasome [93, 95].
A closer examination of inﬂammasome components
revealed that the cytoplasmic receptor NALP3 (NATCHT-
, leucine-rich-repeat- and pyrin-domain-containing protein
3; also known as NLRP3 or cryopyrin) and its adaptor
protein, ASC (apoptosis-associated speck-like protein con-
taining a caspase recruitment domain-CARD), are essential
for sensing viral DNA, as macrophages from mice deﬁcient
in either of these proteins had signiﬁcantly reduced inﬂam-
masome activation in response to adenoviruses. NALP3
and ASC are thought to function in the recruitment of
caspase-1 to the inﬂammasome complex, which thereby
leads to the maturation of pro-IL-1β. An established model
of adenovirus infection in mice was used to demonstrate
that NALP3, ASC and caspase-1 were all required for a
maximal immune response to DNA viruses in vivo [95].
As evidence that the inﬂammasome response operates
independently of other known DNA-sensing mechanisms,
it was shown that, following exposure to adenovirus DNA,
caspase-1 processing was intact in macrophages that lack
both TLR9 and the TLR adaptor protein MyD88. Therefore,
inﬂammasome activation is required in vitro and in vivo for
mounting eﬀective immune responses against DNA viruses,
(e.g. Production of anti-DNA autoantibodies). It seems that
the inﬂammasome response operates independently of other
known DNA-sensing mechanisms.
Interestingly, the presence of nonviral DNA in the cyto-
plasm (of Escherichia coli, mammalian cells, or synthetically
derived) also initiated inﬂammasome activation in THP-1
cells and mouse macrophages. However, such a response was
not elicited by mammalian RNA, polyinosinic–polycytidylic
acid or RNA viruses, demonstrating that inﬂammasome
activation is speciﬁcally triggered by DNA [95]. It has been
conﬁrmed that, the inﬂammasome pathway is distinct and
independent from the type I IFN response that is triggered
following DNA recognition in the cytoplasm [95].Thus, in
addition to identifying a new pathway for host and microbial
DNA recognition, the studies described might provide clues
to the pathology of autoimmune diseases such as systemic
lupus erythematosus (SLE) and chronic arthritis, which
are often associated with autoreactive antibodies speciﬁc
for self DNA and increased levels of IL-1β. That such
conditions might involve aberrant inﬂammasome function
is a possibility that warrants further investigation [94].
Furthermore, clinical research studies have shown that anti-
DNA autoantibodies isolated from patients with rheumatoid
arthritis have signiﬁcant pathogenic and clinical impact on
the disease, while their only heavy and light chain variable
single domains hydrolyze both double and single-stranded
DNAs without sequence speciﬁcity [96, 97]. Given the
fact that, very recently [72, 98] the free light and heavy
chains with hydrolytic activity upon viral dsDNA have
been discovered, as a part of so far nonidentiﬁed immune
proﬁle in sea turtle Trachemyus scripta. This discovery
rises the question whether catalytic properties of anti-DNA
antibodies have a broader, phylogenetic signiﬁcance and the
autoimmunity phenomenology is the creative, long-lasting
product of the evolution across the phylogenetic tree [72,
98].
9.4. The Relevance of Pathogenic Anti-DNA Antibodie’s Idio-
types. Themostdetailedexperimentalstudiesonthissubject
are coming from the group of Shoenfeld et al. It is impossible
to analyze each step of this moir´ e then a decade-long
research, but we shall mention the most illustrative examples
that should ﬁt into this context. Since the idiotypic network
is an important mechanism for controlling the immune
repertoire, [33, 36–38, 41, 47, 99] Shoenfeld et al. [100]Autoimmune Diseases 15
have tested anti-idiotypic modulation employing concen-
trated speciﬁc natural polyclonal anti-double-stranded (ds)
DNA anti-idiotypic antibodies obtained from a commer-
cial IVIG in the treatment of experimental SLE. Speciﬁc
natural polyclonal anti-dsDNA anti-idiotypic antibodies
(IVIG-IDs) were aﬃnity puriﬁed from IVIG on an anti-
dsDNA±Sepharose column constructed from anti-dsDNA
idiotypes (ID) aﬀnity puriﬁed from 55 patients with active
SLE [100]. NZB/W F1 mice were treated i.v. with 3 weekly
injections of IVIG-ID (2mg/kg/injection) or regular IVIG
(400mg/kg/injection) both before (age 8 weeks) and after
developing anti-dsDNA antibodies at the age of 21 ± 22
weeks [100]. The IVIG-ID-treated mice showed a decline
in the titer of anti-dsDNA antibodies during the treatment,
reaching maximum suppression 1 week after the last injec-
tion. A signiﬁcant diﬀerence in the proteinuria level in the
IVIG-ID-treated group compared to the control group was
observed.ImmunohistologyshoweddiﬀerentpatternsofIgG
deposition, with mesangial and capillary wall deposits in
controls and in the IVIG-treated group, but only mesangial
deposits in the IVIG-ID-treated group. The survival time of
the IVIG-ID-treated group was longer than the IVIG-treated
group. Treatment with concentrated speciﬁc anti-dsDNA
anti-ID prepared from commercial IVIG has been shown to
be more eﬀective in suppressing the humoral reaction and
clinicalsignsofSLEthannativeIVIG.Theauthorsconcluded
that those results point to the considerable regulatory role of
anti-ID in the mechanism of action of IVIG in SLE [100].
Later on, in another approach of the same group,
intravenous polyclonal immunoglobulins (IVIGs) were used
as a therapy of autoimmune diseases and especially in
conventional therapy resistance cases of SLE [40]. The main
mechanism by which IVIG exerts its eﬀect in autoimmunity
entails the existence of speciﬁc anti-idiotypic antibodies
in the compound against idiotypes of autoantibodies.
Pathogenic idiotypes of autoantibodies were employed in
the past to induce experimental autoimmune diseases via
active immunization [40, 100]. In this study, a speciﬁc
IVIG (sIVIG) was constructed from a commercial IVIGs
absorption on an column of pathogenic idiotype and elution
of the bound following immunoglobulins. It was found
that the sIVIG was more eﬀective than IVIG in suppressing
murine SLE. Peptides obtained out from a library via the
sIVIG were found to be eﬀective in replacing the idiotypes
of anti-DNA antibodies. sIVIG absorbed on a Id peptides
column were found to be as eﬀective in experimental murine
SLE as sIVIG generated on an Id column. The “ﬁshed” Id
peptides enable the commercial production of sIVIG [40].
In parallel, peptides derived from a pathogenic idiotype
were also employed for therapeutical purposes in human
phase I, II studies and suppressed SLE following active
immunization. Thus, the idiotypic network proposed by
Jerne in 1974 (as we already mentioned above) led to at
least two novel therapeutic avenues in autoimmunity, by
and large, and in SLE speciﬁcally [40]. Taken together,
and in context of vaccine trials with speciﬁc idiotypes,
these results indicate the necessity for deeper insight into
possible mechanism of action of relevant idoitypic anti-
DNA autoantibodies to enlighten their potential targeted
therapeutic role in the spectrum of the entire mosaic of
autoimmunity.
10. Take-Home Messages
(i) An essential criterion for the study of anti-DNA
autoantibodies is their high purity.
(ii) The novel magnetic bead-based method for isolation
and puriﬁcation of anti-ssDNA autoantibodies has
been developed, thus enabling the study of this
unique subset.
(iii) Anti-DNA autoantibodies seem to have dual func-
tion: hydrolysis and cytotoxicity.
(iv) Mouse monoclonal and human polyclonal antiss-
DNA autoantibodies hydrolyze Gololobov’s single
stranded nucleotide sequence.
(v) The hydrolytic and cytotoxic activities of anti-DNA
produce pathological symptoms during an attempt
of the host to protect against the nucleic acids of
microbes.
(vi) Environmental factors such as some drugs, pristine,
phthalates, infection, and some vaccines can alter the
anti-DNA antibody response in mice and probably in
humans.
(vii) Some mechanisms of anti-DNA autoantibody secre-
tion involve Toll-like receptor 9, inﬂammasomes, and
DNA-sensing proteins.
(viii) Idiotypic anti-DNA autoantibodies are pathogenic
and can be used for vaccination.
(ix) Drug-induced lupus does not induce production of
anti-DNA autoantibodies.
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